Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method.

Antimicrobial agents and chemotherapy - 1 Nov 2013

Howard Susan J, Lass-Flörl Cornelia, Cuenca-Estrella Manuel, Gomez-Lopez Alicia, Arendrup Maiken C

Abstract excerpt

Isavuconazole is a novel expanded-spectrum triazole, which has recently been approved by the FDA as an orphan drug to treat invasive aspergillosis and is currently being studied in phase III clinical trials for invasive candidiasis. The susceptibility of relatively few clinical isolates has been reported. In this study, the isavuconazole susceptibilities of 1,237 Aspergillus and 2,010 Candida geographically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aspergillosis
Share to Aspergillus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Candida

Share to Drug Dosage Calculations

Share to Drug Resistance, Fungal

Share to Nitriles

Share to Pyridines

Share to Triazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 23959309
DOI: 10.1128/AAC.01111-13
PMCID: PMC3811258

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method.PMID 23959309Read ↗

Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolatesSemantic proximity Read ↗

Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method.Semantic proximity Read ↗

EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast IsolatesSemantic proximity Read ↗

Identification and antifungal susceptibility patterns of reference yeast strains to novel and conventional agents: a comparative study using CLSI, EUCAST and Sensititre YeastOne methodsSemantic proximity Read ↗

In vitro antifungal susceptibility profile and genotypic characterization of clinical Aspergillus isolates in Eastern China on behalf of Eastern China Invasive Fungi Infection Group.Semantic proximity Read ↗

In Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents.Semantic proximity Read ↗

Rezafungin In Vitro Activity against Contemporary Nordic Clinical Candida Isolates and Candida auris Determined by the EUCAST Reference Method.Semantic proximity Read ↗

Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method.Semantic proximity Read ↗

Development and validation of next-generation sequencing-based clinical test for triazole resistance prediction in Aspergillus fumigatus.Semantic proximity Read ↗

EUCAST Determination of Olorofim (F901318) Susceptibility of Mold Species, Method Validation, and MICsSemantic proximity Read ↗

Epidemiological characteristics of invasive Aspergillus isolates: Morphology, drug susceptibility, and mutations in azole drug targets.Semantic proximity Read ↗

A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical BreakpointsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.